Financials CEL-SCI Corporation

Equities

CVM

US1508376076

Pharmaceuticals

Real-time Estimate Cboe BZX 12:18:21 2024-05-06 pm EDT 5-day change 1st Jan Change
1.675 USD +2.76% Intraday chart for CEL-SCI Corporation +21.28% -37.13%

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 313.4 492.5 472.9 134 59.08 87.99 - -
Enterprise Value (EV) 1 313.4 492.5 472.9 134 54.93 74.72 72.66 87.99
P/E ratio -12.6 x -15.5 x -12.2 x -3.55 x -1.71 x -3.2 x -3.29 x -6.79 x
Yield - - - - - - - -
Capitalization / Revenue 677 x 881 x - - - - 19.3 x 11.4 x
EV / Revenue 677 x 881 x - - - - 15.9 x 11.4 x
EV / EBITDA - - - -4.16 x -2 x -1.86 x -2.94 x -
EV / FCF - - - -7.1 x -2.37 x -1.9 x -2.77 x -
FCF Yield - - - -14.1% -42.3% -52.6% -36.1% -
Price to Book - - - - 4.49 x 2.86 x 2.26 x -
Nbr of stocks (in thousands) 35,055 38,624 43,028 43,367 47,260 53,979 - -
Reference price 2 8.940 12.75 10.99 3.090 1.250 1.630 1.630 1.630
Announcement Date 12/16/19 12/29/20 12/21/21 12/27/22 12/21/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.4628 0.5587 - - - - 4.567 7.7
EBITDA 1 - - - -32.23 -27.52 -40.18 -24.7 -
EBIT 1 -20.2 -28.99 -36.19 -36.06 -31.48 -27.6 -25.14 -16.5
Operating Margin -4,364.15% -5,188.32% - - - - -550.47% -214.29%
Earnings before Tax (EBT) 1 -22.13 -30.28 -36.36 -36.7 -32.37 -28.4 -25.89 -16.5
Net income 1 -22.13 -30.28 -36.36 -37.63 -32.37 -28.4 -25.89 -17.5
Net margin -4,783.28% -5,419.57% - - - - -566.89% -227.27%
EPS 2 -0.7100 -0.8200 -0.9000 -0.8700 -0.7300 -0.5100 -0.4950 -0.2400
Free Cash Flow 1 - - - -18.88 -23.21 -39.33 -26.26 -
FCF margin - - - - - - -575.04% -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 12/16/19 12/29/20 12/21/21 12/27/22 12/21/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA - - -8.573 -7.741 -7.965 -6.662 - - - - - - -
EBIT 1 -8.474 - -9.552 -8.719 -8.948 -7.651 -8.176 -8.182 -7.468 - -6.9 -7.2 -7
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -8.205 - -9.823 -9.633 -8.462 -7.854 -8.343 -8.367 -7.631 - -7.1 -7.4 -7.2
Net income 1 -8.205 -8.783 -9.823 -9.927 -9.097 -8.025 -8.343 -8.367 -7.631 -6.71 -7.1 -7.4 -7.2
Net margin - - - - - - - - - - - - -
EPS 2 -0.1900 -0.2000 -0.2300 -0.2300 -0.2100 -0.1800 -0.1900 -0.1900 -0.1600 -0.1400 -0.1400 -0.1300 -0.1100
Dividend per Share - - - - - - - - - - - - -
Announcement Date 12/21/21 2/11/22 5/13/22 8/12/22 12/27/22 2/14/23 5/12/23 8/11/23 12/21/23 2/14/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 - - - - 4.15 13.3 15.3 -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - - - -18.9 -23.2 -39.3 -26.3 -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - - 0.2800 0.5700 0.7200 -
Cash Flow per Share - - - - - - - -
Capex 1 - - - 0.64 0.36 3.62 3.14 -
Capex / Sales - - - - - - 68.75% -
Announcement Date 12/16/19 12/29/20 12/21/21 12/27/22 12/21/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.63 USD
Average target price
7.7 USD
Spread / Average Target
+372.39%
Consensus
  1. Stock Market
  2. Equities
  3. CVM Stock
  4. Financials CEL-SCI Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW